Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117079 | 0.79 | LIPA (0.31) | — | |
| SCHEMBL22519405 | 0.77 | LMNA (0.46) | CHRM3CHRM2CHRM1LMNACYP2C9 | |
| SCHEMBL13075331 | 0.77 | NCF1 (0.38) | CHRM3CHRM1CHRM4CHRM5 | |
| SCHEMBL3817178 | 0.76 | BRD4 (0.47) | CHRM3CHRM2CHRM1LMNACYP2C9 | |
| SCHEMBL10248633 | 0.76 | — | — | |
| SCHEMBL3817176 | 0.76 | BRD4 (0.47) | CHRM3CHRM2CHRM1LMNACYP2C9 | |
| SCHEMBL10248640 | 0.76 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL7500572 | 0.75 | EPHX2 (0.37) | ALDH1A1TSHR | |
| SCHEMBL18438801 | 0.75 | ALOX5 (0.34) | ALDH1A1TSHR | |
| SCHEMBL14898440 | 0.75 | CHRM3 (0.35) | CHRM3CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275079-A1 | 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis | GLAXO GROUP LIMITED | 2008-11-06 | — | — | US | disclosed |
| US-20080275079-A1 | 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis | GLAXO GROUP LIMITED | 2008-11-06 | — | — | US | disclosed |
| US-20080234315-A1 | M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
| US-20080234315-A1 | M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
| WO-2007016650-A2 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016639-A2 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234315-A1 | M3 Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20080275079-A1 | 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis | CHRM3, EDNRB, BDKRB2 | CHRM3 1/4885CHRM2 7/4885CHRM1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.